Pfizer & Merck Q2 Earnings Preview: New Growth Drivers Under Pressure as Legacy Businesses Weigh
Alina Collins
Pfizer and Merck report second-quarter results Tuesday, with analysts expecting year-over-year profit declines at both firms — new growth lines have not yet filled the gap left by shrinking legacy products, the shared challenge defining this earnings cycle.
What numbers is the market watching?
Pfizer's consensus EPS (earnings per share — the profit each share of stock represents) is $0.68, down 12.8% year over year.
Merck also faces year-over-year EPS pressure; the market has not settled on a precise consensus figure.
This means → neither company is merely "slowing down" — profits are actively contracting, and investors will focus on how management explains the trajectory.
Why are profits shrinking?
Both drugmakers' legacy core products are generating less revenue — that is the primary driver of the earnings decline.
New growth businesses are advancing, but have not yet scaled enough to close the revenue gap the old products left behind.
In plain terms = the old cash cows are fading, the new ones have not matured, and the companies are stuck in a transition gap between the two.
What does this mean for investors?
After Tuesday's release, the market will look beyond "how much did they earn" to management guidance on when new products start scaling.
If new-product revenue growth disappoints, the "transition gap" narrative hardens and shares face near-term pressure.
This reflects a pivotal moment in big-pharma product cycles — ugly short-term income statements do not necessarily mean the long-term thesis is broken, but concrete data is needed to prove it.
Content is for reference only, not financial advice.